Experts: key drug facts often left off FDA labels
WASHINGTON — Did you know that Lunesta will help you fall asleep just 15 minutes faster? Or that a higher dose of the osteoporosis drug Zometa could damage a cancer patient’s kidneys and raise their risk of death?
Chances are you didn’t, and neither did your doctor. Much of what the Food and Drug Administration knows about a drug’s safety and effectiveness is not included on the label, say two drug safety experts who are calling on the agency to make that information more accessible.
In this week’s issue of the New England Journal of Medicine, researchers from Dartmouth College argue that drug labels don’t reflect the nuanced decisions the FDA makes when deciding to approve a drug. The editorial from Drs. Lisa Schwartz and Steven Woloshin recommends easy-to-read fact boxes to help patients weigh the benefits and risks of medications.
If drug labels sometimes exaggerate benefits and play down drug risks, the authors say there’s a very good reason: they are written by drugmakers.
While FDA must approve the final labeling, the actual language is drafted by the manufacturer, with input from FDA scientists.
The labeling is based on results from company studies, which generally compare results for patients taking the drug versus those taking placebo.
If FDA decides the drug’s ability to treat or prevent a disease outweighs its side effects, the agency is obligated to approve it. But Schwartz and Woloshin point out that benefits may be slim and potential harms may not be fully understood.
“The take home point is that just because a drug is approved doesn’t mean it works very well,” said Schwartz, in an interview with the Associated Press. “You really need to know more to see whether it’s worth the cost.”
Schwartz and Woloshin say FDA labeling frequently fails to provide a full picture of a drug’s effects.
In the case of Sepracor Inc.’s blockbuster sleeping pill Lunesta, it’s virtually impossible to tell how well the drug works based on the labeling, which only indicates that it worked better than placebo, or a dummy pill.
Only by wading through the FDA’s 403-page internal review of Lunesta do the details emerge: patients fell asleep 15 minutes faster and slept 37 minutes longer, on average.
“Lunesta patients still met criteria for insomnia and reported no clinically meaningful improvement in next-day alertness,” the authors state.
Despite that lackluster finding, the drug has grown into a $600 million-a-year drug for Sepracor, helped by the company’s advertisements featuring a green Lunesta moth.
FDA review documents can also hide critical safety information.
The authors point to the example of Novartis’ Zometa, which was approved in 2001 to prevent skeletal fractures in cancer patients with brittle bones. The drug was approved in both 4-mg and 8-mg doses, despite FDA findings of increased kidney damage and death with the higher dose.
FDA went back and added language about kidney toxicity in 2008, but the information about death rates is still missing from the label.
While FDA reviews are posted online, they are often hundreds of pages long and written in extremely dense medical language.
Woloshin and Schwartz recommend FDA provide reader-friendly summaries of its drug reviews, to supplement industry-drafted drug labeling.
Earlier this year, the FDA’s panel of communication experts recommended the agency adopt fact boxes for all announcements about drug risks and benefits. Woloshin and Schwartz said they have met with FDA leadership to discuss the proposal.
A spokeswoman for the FDA declined to comment Wednesday afternoon.
In a study comparing comprehension of drug benefits, patients showed significantly better understanding with fact boxes versus traditional drug advertising. Seventy percent of patients viewing the boxes correctly identified a superior heart burn medication, versus just 8 percent who viewed drug advertisements, according to the 2006 study by Schwartz and Woloshin.
Related News
Biogen Idec, Biovitrum will advance potential hemophilia drugOctober 19th, 2009 Biogen, Biovitrum advancing hemophilia drugNEW YORK — Biogen Idec Inc. and Biovitrum said Monday they will move a potential hemophilia B treatment into a late-stage study.
FDA says Pfizer's pill Selzentry appears safe for broader use against HIVOctober 6th, 2009 FDA sees no safety issues with Pfizer HIV drugWASHINGTON — The Food and Drug Administration said Tuesday an HIV drug from Pfizer appears safe for expanded use in patients who have not already taken other drugs to combat the virus. However, the FDA said Pfizer studies paint a mixed picture of its drug's effectiveness.
Antibiotic could be the new stroke treatmentOctober 6th, 2009 WASHINGTON - The antibiotic minocycline may offer new and more effective treatment for stroke patients, says a new study. The research, published in the open access journal BMC Neuroscience, describes the safety and therapeutic efficacy of the drug in animal models.
'Cervical cancer jab as deadly as the disease'October 4th, 2009 LONDON - A leading expert who helped develop the cervical cancer vaccine has claimed that the jab may be more deadly than the disease. Dr Diane Harper, the University of Missouri-Kansas, warned the vaccine was being "over-marketed" and the information about its potential side effects was not as popular.
Drug combo better than individual medications for treating chronic painOctober 1st, 2009 WASHINGTON - A combination of two commonly prescribed drugs offers a much more effective treatment for people with debilitating neuropathic pain than if they take either of the medications individually, according to a study by Queen's University researchers. When given both an anti-seizure drug (gabapentin) and an antidepressant (nortriptyline), patients suffering from neuropathic pain caused by nerve damage or disease experienced less pain than when they took one or the other individually, reports Dr.
FDA tells doctors reformulated blood thinner heparin will be safer, but less potentOctober 1st, 2009 FDA tells doctors new heparin formula less potentWASHINGTON — The Food and Drug Administration is alerting doctors that a widely used blood thinner has been reformulated to improve its safety, though the change could open the door to dosing errors. The FDA said Thursday new heparin vials scheduled to begin shipping next week will be 10 percent less potent than the original blood thinner.
FDA notes liver damage risks with GlaxoSmithKline's kidney cancer drugOctober 1st, 2009 FDA questions safety of Glaxo kidney cancer drugWASHINGTON — Federal regulators said Thursday an experimental kidney cancer drug from GlaxoSmithKline may cause liver problems, potentially outweighing its ability to slow the disease. London-based Glaxo wants the Food and Drug Administration to approve its pazopanib pills for advanced kidney cancer, a rare but deadly form of the disease.
FDA to revamp strategy on product safety announcements following years of outside criticismSeptember 30th, 2009 FDA revamps strategy on product safety newsWASHINGTON — The Food and Drug Administration is laying out plans to improve its public announcements on food and drug safety, more than three years after federal advisers recommended major changes. The agency says it will begin studying public response to its announcements on potentially dangerous food and drugs.
Roche says a study on Avastin in early-stage breast cancer halted over safety concernSeptember 25th, 2009 Enrollment in Avastin breast cancer study haltedNEW YORK — Swiss drug developer Roche said Friday six cases of patients with heart failure symptoms prompted a halt to enrollment in a National Cancer Institute sponsored study of its blockbuster drug Avastin. The U.S. National Cancer Institute and U.S.
'Spectacular' treatment for skin cancer developedSeptember 24th, 2009 LONDON - American scientists have developed, what is being hailed as a "simply spectacular" treatment for skin cancer that could shrink the tumours at a "rapid and dramatic" rate in patients whose disease had spread. The results of the drug trial are significant because skin cancer, though curable when caught early, usually become fatal when it spreads to other parts of the body.
FDA panel back approval for abuse-resistant OxyContin pillSeptember 24th, 2009 FDA panel backs reformulated OxyContin pillWASHINGTON — Federal health advisers on Thursday recommended approval for a new version of the painkiller OxyContin that is designed to be harder to abuse. A Food and Drug Administration panel of experts voted 14-4 in favor of the reformulated OxyContin from Purdue Pharma.
India to have national patient safety policy: AzadSeptember 14th, 2009 NEW DELHI - India will soon have a National Patient Safety Policy to provide patients with a safer healthcare environment, Health Minister Ghulam Nabi Azad said here Monday. Noting that the country has many national programmes to control and eradicate various diseases but nothing on patient safety, he said: We are proposing to put in place a National Patient Safety Policy.
HHS Secretary Sebelius announces new food safety Web site designed to streamline food infoSeptember 9th, 2009 Sebelius announces new food safety Web siteWASHINGTON — The Obama administration is rolling out a new Web site designed to streamline food safety information for consumers. Health and Human Services Secretary Kathleen Sebelius announced the new Web site — www.foodsafety.gov — on Wednesday during the Consumer Federation of America's food policy conference.
FDA panel says Allos Therapeutics drug will benefit patients with rare form of lymphomaSeptember 2nd, 2009 FDA panel backs Allos Therapeutics' cancer drugWASHINGTON — Federal health experts voted Wednesday in favor of an experimental cancer drug from Allos Therapeutics for patients with a rare form of cancer. A spokeswoman for the Food and Drug Administration said the agency's panel of oncology experts voted 10-4 that the company's drug pralatrexate would likely benefit patients with T-Cell lymphoma.
FDA panel says Genzyme did not conduct study necessary to prove benefit of leukemia drugSeptember 1st, 2009 FDA panel wants more data on Genzyme cancer drugWASHINGTON — A panel of cancer experts has issued a negative review of a leukemia drug from Genzyme, saying more data is needed to establish its safety and efficacy for older patients. The Food and Drug Administration's oncology panel voted 9-3 Tuesday that Cambridge, Mass.-based Genzyme should be required to conduct a larger, comparison study to prove its drug is safe and effective.
